NCT02210299

Brief Summary

People are, especially in industrialized countries, exposed to a growing number of ubiquitous chemical substances. It thus increases human exposure pathways: diet, inhalation, soil and dust dermal contact…), notably for semi-volatile organic compounds. Diet is generally sought to contribute the most to total exposure for many chemicals, the relative contribution of each pathway is nevertheless poorly described, and can be different among populations. This is in particularly the case For young children, who can be more exposed via the environment, because of frequent contact with object and dust and hand to mouth behaviors. Children are in addition considered more sensitive to chemical risk due to their maturating systems. In this context, the objective of this project is to characterize the young children's exposure to a particular class of semi volatile organic compounds. It will encompass the relative contribution of different pathways to the external dose, and to try to match the internal and external doses with a physiologically based pharmacokinetic (PBPK) model for molecules for which it is possible. The present demand concerns a feasibility study on 2 children, for Perfluorinated Alkylated Substances (PFAS), used in numerous consumer products.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2014

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 5, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 6, 2014

Completed
26 days until next milestone

Study Start

First participant enrolled

September 1, 2014

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

June 10, 2015

Status Verified

June 1, 2015

Enrollment Period

8 months

First QC Date

August 5, 2014

Last Update Submit

June 9, 2015

Conditions

Keywords

Healthy young children (2-6 months ; 12-18 months)

Outcome Measures

Primary Outcomes (1)

  • Feasibility recruitment

    Main objective of this feasibility study is to set the scientific consortium to recruit and study 2 young children's exposures. Main judgement criteria : Effective enrolment of 2 young children during their consultation to Rennes hospital, from those having a blood sampling for medical purposes, and house survey.

    3 months

Secondary Outcomes (1)

  • Protocol validation

    1 year

Study Arms (1)

Exposure study

OTHER

2-6 months-old children and 12-18 months-old children

Other: Exposure study

Interventions

Sampling of blood, food, water, air and dust and delivery of dietary questionnaire

Exposure study

Eligibility Criteria

Age6 Months - 18 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Young children (2-6 months ; 12-18 months)
  • In outpatient pediatric or pediatric surgery ;
  • From their homes ;
  • With home located less than 30km from Rennes ;
  • Living at their home (not at childcare facility or child-minder);
  • With a scheduled blood sampling apart from this study ;
  • For child 2 - 6 months :
  • With diet exclusively based on milk (maternal exclusively or commercial exclusively)
  • In case of breastfeeding, with mother accepting milk sampling ;
  • With a free, enlightened and signed written consent from the parents.
  • Breastfeeding mother :
  • \> 18 years ;
  • Exclusive breastfeeding ;
  • With a free, enlightened and signed written consent.

You may not qualify if:

  • Children :
  • Metabolic illness ;
  • Renal or hepatic insufficiency ;
  • Malabsorption
  • With known HIV+, HBV+, HCV+, CMV+ serology
  • Simultaneously participating to other biomedical survey
  • For breastfeeding mother :
  • Under legal protection (judicial protection, guardianship) ;
  • mixed breastfeeding ;
  • with Known HIV+, HBV+, HCV+, CMV+ serology

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rennes Hospital University

Rennes, Brittany Region, 35033, France

Location

Study Officials

  • Philippe Glorennec, PhD

    Inserm UMR 1085 - Institut de Recherche sur la Santé, l'Environnement et le Travail

    STUDY CHAIR
  • Florence Rouget, MD

    Rennes University Hospital

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 5, 2014

First Posted

August 6, 2014

Study Start

September 1, 2014

Primary Completion

May 1, 2015

Study Completion

May 1, 2015

Last Updated

June 10, 2015

Record last verified: 2015-06

Locations